Hologic (HOLX) Hits a New 52-Week High: What's Driving It?
Zacks Investment Research | Jan 10, 2021 10:34PM ET
Shares of Hologic (NASDAQ:HOLX), Inc. industry it belongs to and 18.3% surge of the Zacks S&P 500 composite.
In fact, Hologic’s shares significantly gained post its first-quarter fiscal 2021 preliminary results announcement on Jan 8. Hologic is also gaining from a slew of recently completed acquisitions. Further, recent regulatory approvals also buoy optimism. However, downsides may result from a stiff competitive landscape and foreign exchange headwinds.
Let's delve deeper.
Impressive Q1 Fiscal 2021 Results/h3
Hologic’s recently released preliminary results for its fiscal 2021 first quarter instill investors’ confidence in the stock. The company’s projection of a reported revenue growth of 89.3% (86.5% at constant exchange rate) looks impressive. Further, organic revenues (or revenues excluding divestitures and the Acessa acquisition) are projected at a stupendous level of 104%, further buoying optimism on the stock.
Other Growth Drivers/h3
Acquisitions: Hologic has, of late, been gaining from a slew of buyouts. The recently completed acquisition of SOMATEX Medical Technologies GmbH, a well-known name in the biopsy site markers and localization technologies space, looks encouraging. Hologic also announced its plans to acquire Biotheranostics, Inc., a privately held commercial-stage company providing molecular diagnostic tests for breast and metastatic cancer. These buyouts are expected to significantly boost Hologic’s business across the globe.
Regulatory Approvals: Investors are upbeat about Hologic’s recent regulatory clearances. The company received the FDA’s approval for its Genius AI Detection technology in December 2020. In November 2020, Hologic received the FDA’s approval for its diagnostic claim for its HIV-1 (human immunodeficiency virus type 1) viral load monitoring assay. The same month, the company received the CE Mark for its new Genius Digital Diagnostics System.
In October 2020, Hologic announced the amendment of the FDA’s Emergency Use Authorization that was initially received for its Aptima SARS-CoV-2 assay (that runs on the company’s fully automated Panther system) in May.
Downsides/h3
Tough Competition: Hologic operates in a highly competitive industry, which includes giants like Siemens. The FDA’s decision to re-classify FFDM devices to class II from class III makes it easier for all medical devices companies to introduce similar products in the market. Subsequently, the approval process for class II devices will require 510(k) clearance rather than the lengthy premarket approval application. This will enable easier approval in the United States, thus intensifying competition among medical device companies.
Foreign Exchange Headwinds: Hologic faces significant business challenges owing to unfavorable foreign currency impacts. This persistent issue has been adversely affecting the company’s overall performance over the past few quarters.
Zacks Rank & Other Key Picks/h3
Currently, Hologic sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks from the broader medical space are Amedisys (NASDAQ:AMED), Inc. Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.